B-cell depletion therapy effective for treating refractory patientsAccording to a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, 36 percent of patients afflicted with refractory systemic lupus erythematosus (SLE or lupus) could notice improvements after undergoing B-cell depletion therapy (BCDT) and do not feel or need standard immunosuppressive agents in the future.

It is worth noting here that reducing the number of B-cells in the system by B-cell depletion therapy is considered as a potential therapy for SLE patients who are unresponsive to other forms of treatment.

It was revealed by co-author of the paper, Professor David Isenberg, from University College London in the United Kingdom that the study results are encouraging and demonstrate that BCDT could be rated as a promising therapeutic option for lupus patients and is effective to reduce the need for continuous immunosuppressive therapy.